CONMED Corp. 10-Q Summary: Quarter Ended June 30, 2002
Business Context and Reporting Period
This Form 10-Q covers the three and six months ended June 30, 2002. CONMED Corporation is a medical technology company specializing in instruments, implants, and video equipment for arthroscopic sports medicine, powered surgical instruments, electrosurgery systems, endoscopy products, and patient care products. The company operates as a single segment.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended 6/30/02 | 6 Months Ended 6/30/02 |
|---|---|---|
| Net Sales | $111,269 | $224,474 |
| Gross Margin | 53.5% | 52.9% |
| Operating Income | $20,339 | $41,148 |
| Net Income | $8,950 | $18,026 |
| Diluted EPS | $0.33 | $0.68 |
| Operating Cash Flow | N/A | $17,881 |
| Total Debt (Current + Long-term) | $257,733 | $257,733 |
| Cash and Equivalents | $877 | $877 |
| Working Capital | $49,165 | $49,165 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 6.8% in the quarter and 6.9% for the six-month period compared to 2001. Growth was driven by arthroscopy (up 8.4% QoQ) and endoscopy (up significantly due to the Imagyn acquisition), partially offset by declines in powered surgical instruments and patient care products.
- Profitability: Net income rose 56.1% for the quarter and 53.6% for the six-month period. Operating margins improved to 18.2% (Q2) and 18.3% (YTD) from 16.1% and 16.4% respectively in 2001.
- Accounting Change: Adoption of SFAS 142 eliminated goodwill amortization, increasing net income by approximately $1.4 million for the quarter and $2.8 million for the six months.
- Debt Reduction: Total borrowings declined to $257.7 million from $367.7 million a year ago, reducing interest expense by $1.5 million (quarter) and $3.2 million (YTD).
Guidance, Outlook, and Risks
- Capital Markets: On May 29, 2002, the company completed a public offering of 3.0 million shares for net proceeds of approximately $66.6 million, used to reduce indebtedness.
- Debt Refinancing: The revolving credit facility expires December 31, 2002. Management is negotiating a new facility, expecting interest costs to rise 75-100 basis points. An extraordinary charge of approximately $1.0 million (net of tax) is anticipated in Q3 2002 related to the extinguishment of the current debt.
- Product Outlook: The company expects the new PowerPro(R) battery-powered product line to resume growth in powered surgical instrument sales once established in the marketplace.
- Risks: Risks include the ability to refinance debt on acceptable terms, competition in patient care and electrosurgery segments, and the need to maintain statistical ratios for the accounts receivable sales agreement.
Investor Verification Checklist
- Verify the terms and interest rate spread of the new credit facility expected in Q3 2002.
- Confirm the timeline for the full market adoption of the PowerPro(R) product line and its impact on orthopedic revenue.
- Monitor the status of the accounts receivable sales agreement and the $36.0 million outstanding balance sold to the conduit purchaser.
- Review the specific breakdown of the anticipated $1.0 million extraordinary charge in the upcoming Q3 filing.
- Assess the sustainability of gross margin improvements given the shift in product mix toward higher-margin arthroscopy and endoscopy.